


ANEMIAS

ABSOLUTE RETIC COUNT



IRON-DEFICIENCY ANEMIA

Epidemiology: pregnant woman, toddlers (9%) and adolescent girls (16%)
Etiology: blood loss
Clinical Presentation: pica and thrombocytosis
Diagnostic Mechanism: CBC, Ferritin, Iron studies.
Diagnostic Results: ↑RDW, ↓MCV, then ↓hgb ↓hct.
 Ferritin <math>< 15</math>
 ↓serum iron, ↑TIBC, ↓transferrin saturation
Treatment: treat underlying cause. Treatment of choice = oral iron replacement.

ANEMIA OF CHRONIC DISEASE

Epidemiology: affects people who have conditions that cause inflammation.
Etiology: hepcidin → ↓iron absorption
Lab results: ↓serum iron, ↓TIBC, -or ↑ferritin
 ↓MCV ↓hgb ↓hct

Epidemiology:
Etiology:
Clinical Presentation:
Diagnostic Mechanism:
Diagnostic Results:
Treatment:

LEAD POISONING

Epidemiology: slightly higher in males. Incidence decreasing.
Etiology: workplace exposure. Unintentional ingestions.
Clinical Presentation: microcytic anemia and basophilic stippling of RBCs (gain granules)
Diagnostic Mechanism: direct measurement of blood lead.
Diagnostic Results: >10 = impaired development. >70 = severe poisoning. ↓MCV and ↓hgb. Basophilic Stippling.
Treatment: edetate calcium disodium (EDTA) IV. Oral chelator if minor.

MEGALOBLASTIC ANEMIAS

Defect in DNA synthesis.
• ↑MCV and immature nucleus

B12 DEFICIENCY ANEMIA

FOLATE DEFICIENCY

Etiology: ↓ intake or absorption, diseases (Crohn's, etc)

malnutrition, malabsorption, drugs

Clinical Presentation: Neurological symptoms

anemia is presenting symptom

Diagnostic Mechanism:

peripheral smear and CBC

Diagnostic Results: ↓ B12, ↑ homocysteine, ↑ methylmalonic acid

hypersegmented (>6) PMN

Treatment: IM B12 injections

treat underlying cause

daily oral folate

APLASTIC ANEMIA

pancytopenia in the peripheral blood, with BMbx showing hypercellularity, arising from a deficiency of hematopoietic stem cells.

Etiology: Inherited. Autoimmune. 50% Idiopathic (radiation, chemo, benzene exposure, EBV, chloramphenicol drug)

Clinical Presentation: Symptoms of anemia, low platelets (bleeding/bruising), and low neutrophil (infections)

Diagnostic Mechanism: rule out other causes of pancytopenia. Bone marrow biopsy → hypocellularity <25%

Diagnostic Results: absolute neutrophil count <500. Platelet count <50,000. Retic count <50,000.

Treatment: supportive (transfusion, EFs), definitive, and T-cell directed immunosuppression.

↳ SCT (if young and otherwise healthy) ↳ anti-thymocyte globulin (ATG) and cyclosporine

HEMOLYTIC ANEMIAS

decreased RBC lifespan


General clinical features: jaundice, ↑ risk of gallstones, splenomegaly, aplastic crisis w/ parvovirus 19, and ↑ folate requirement.

Laboratory evidence: evidence for ↑ RBC production → ↑ retic count

evidence for ↑ RBC destruction → ↑ LDH ↑ bili ↓ haptoglobin

morphologic evidence of RBC damage → schistocytes, spherocytes, bite cells

CONGENITAL



HEREDITARY SPHEROCYTOSIS

membrane defect

Epidemiology: most common defect leading to anemia, 1/5000 Europeans. Autosomal dominant.

Etiology: defect in proteins of the membrane skeleton (spectrin or ankyrin)

spherocyte formation due to progressive loss of membrane and surface area.

Clinical Presentation: increased hemolysis and abdominal pain with trivial illnesses.

Diagnostic Mechanism: peripheral smear, Flow cytometry using ESM (eosin 5' maleimide)

Diagnostic Results: Spherocytes → more prone to lysis. ↑ free hgb

Treatment: folate supplementation. Splenectomy if refractory/symptomatic.

G6PD DEFICIENCY

enzymatic defect

Heinz bodies → bite or blister

Epidemiology: X-linked. In Africans, protein loses activity with age. Mediterranean - baseline low activity.

Etiology: hemoglobin loses protection from oxidative damage → denatured → precipitate as Heinz bodies.

Clinical Presentation: max anemia 7-10 days after exposure. ↑ retics - body compensates

Diagnostic Mechanism: peripheral smear. Measurable blood test.

Diagnostic Results: **bite or blister cells**

Treatment: Supplement folate. Avoid oxidant agents (sulfa drugs, vit K, fava beans, mothballs, anti-mal)

IMMUNE-MEDIATED HEMOLYSIS

acquired hemolytic anemia

AUTOIMMUNE

WARM ANTIBODIES

COLD ANTIBODIES

Epidemiology

NA

Idiopathic, infection, lymphoproliferative disease.

Etiology

IgG against RBCs at 37° → No agglutination

IgM against RBCs at <32° → agglutination

Clinical Presentation

Splenomegaly, jaundice, ± anemia

Ischemia in extremities.

Diagnostic Mechanism

Coombs Test - IgG or C3 bound DIRECTLY to RBC

Coombs Test

Peripheral smear

Peripheral smear

Diagnostic Results

+ coomb's - direct and indirect. **+IgG** ± C3

+ coomb's test. Doesn't tell you cold vs. warm

Spherocytes

RBC agglutination (clumping)

↑ reticulocytes, ↑ bili, ↑ LDH.

Treatment

Mainstay = **immunosuppression** corticosteroids rituximab

Keep patient **warm**. Blood and IV fluids warmed.

RBC transfusion, if symptomatic.

steroids + splenectomy → **ineffective**. Rituximab ✓

Spherocytes

Clumping

THALASSEMIA

Heinz bodies

BETA

Epidemiology: most common in southern Europe. SE Asia, Africa, middle east. **Mediterraneans**.

Etiology: mutations (β^0 - absent β globin synthesis. β^+ - decreased production.)

Clinical Presentation: anemia, splenomegaly, bone deformities, iron overload (bronze skin and liver failure)

Diagnostic Mechanism: hemoglobin electrophoresis.

↳ due to transfusion and ↑ RBC

Diagnostic Results: α_4 tetramers. Absent (or deficient) normal hgbA. Microcytic. ↑ RBC.

Treatment: turn off erythropoietin. Gene therapy. Get iron out of body.

Transfusion-dependent →

ALPHA

Epidemiology: SE Asia and West Africa.

Asians ←

↳ African Americans (5-7%)

$\alpha\alpha/\alpha-$

$\alpha\alpha/--$ OR $\alpha-/ \alpha-$

$\alpha-/--$ HgH

Etiology: one alpha gene deletion

↳ cis deletion ↳ trans deletion

β_4 tetramers → Heinz bodies

Clinical Presentation: silent. Not anemic.

Mild anemia.

Variable. Splenomegaly

Diagnostic Mechanism: Hgb electrophoresis normal

Hgb electrophoresis normal

Peripheral smear

Diagnostic Results: minimal microcytosis

microcytosis with MCV ~70

Bite cells ↓ Hgb ↓ MCV ↑ RDW

Treatment: not treated

Not treated

HYDROS FETALIS: $--/--$. No alpha chains form.

• Predominant chain synthesized is γ_4 tetramers = **Hemoglobin Barts**.

• In utero death.

Treatment: in utero by exchange transfusions or in utero bone marrow transplantation.

SICKLE CELL DISEASE

Epidemiology: 1/12 AAs carry trait. 1/500 have disease. 1/1000-5000 hispanic-Americans. Middle east, mediterranean, India.

Etiology: missense mutation in 6th AA in B chain forms HbS.

Hypoxia and acidosis → HbS polymerizes and cells sickle. Eventually become irreversibly sickled → obstruct vessel.

SS = sickle cell anemia. SC = more mild. SB-thal = B⁰ indistinguishable from SS. SP⁺ = more mild.

Clinical Presentation: hematologic → anemia, leukocytosis, thrombocytosis.

• by adulthood, functionally asplenic (howell-Jolly bodies and infections)

• thromboses → increased risk for venous clots

Sickle cell crises → splenic sequestration - massive splenomegaly and hypovolemic shock

aplastic crisis - parvovirus 19 leads to marrow suppression

painful (episode) crisis - painful episodes of acute vascular occlusion

acute chest syndrome → hypoxemia, new infiltrate, new fever, chest pain, dyspnea.

• most frequent cause of death.

pulmonary hypertension

stroke → median age = 5. Due to disordered blood vessels.

Diagnostic Mechanism: hemoglobin electrophoresis

Diagnostic Results:

Treatment: hydroxyurea - increases HbF decreasing HbS. AE - bone marrow suppression. Not used if preg.

exchange transfusion - stroke

simple transfusion - acute chest or pre-operative.

antibiotics and oxygen for acute chest

THROMBOCYTOPENIA

too few platelets

Under production

Peripheral Destruction

Splenic Sequestration

marrow failure

myelodysplasia
aplastic anemia
vit deficiency

marrow infiltration

tumor
granulomatous
fibrosis
leukemias
lymphomas

marrow toxins

drugs
radiation
infection
alcohol

Non-Immune

DIC
TTP

Schistocytes

Immune

Antibody-mediated

DISSEMINATED INTRAVASCULAR COAGULATION

Schistocytes

Epidemiology: NA

Etiology: abnormal activation of coagulation, consumption of clotting factors, destruction of platelets and activation of fibrinolysis. Triggered by ↑TF in wrong place.

Clinical Presentation: oozing, bruising, sepsis

Diagnostic Mechanism: PT and aPTT. CBC. Peripheral smear.

Diagnostic Results: ↑PT, ↑aPTT, ↓platelets, ↓fibrinogen, ↑D-dimers, Schistocytes

Treatment: underlying cause. Transfusion of platelets, clotting factors, or fibrinogen.

THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) Schistocytes

Epidemiology: sporadic. Autoantibody/inhibitor against protease.

Etiology: absence/deficiency of **ADAMTS 13 protease** that cleaves vWF. UL multimers bind platelets and make platelet plugs in microvasculature.

Clinical Presentation: **PENTAD** - MAHA, low platelets, fever, neurologic manifestations, renal manifestations

Diagnostic Mechanism: CBC. Peripheral smear. Measure activity levels of ADAMTS-13.

Diagnostic Results: ↓ **Platelets**. **Schistocytes**. ↑ LDH and ↑ bili.

Treatment: **plasma exchange** AVOID platelet transfusion.

HEMOLYTIC UREMIC SYNDROME (HUS)

Epidemiology: seen more in **pediatrics** → better prognosis

Etiology: precipitated by diarrheal illness (E. coli O157: H7 or Shiga toxin)

Clinical Presentation: ↓ neurological sequelae. ↑ **renal manifestations**. Usually starts w/ **bloody diarrhea**.
atypical HUS → without diarrheal prodrome. Needs two hits.

Diagnostic Mechanism:

Diagnostic Results:

Treatment: **eculizumab** and **PLEX**

HIT Heparin-induced Thrombocytopenia

Epidemiology: 1/3 pts treated with heparin. **Older pts** and after orthopedic surgeries.

Etiology: caused by **antibodies against complex of heparin/PFH**.

Clinical Presentation: can lead to **thrombosis**

Diagnostic Mechanism: CBC

Diagnostic Results: ↓ **Platelets** on heparin.

Treatment: **STOP** heparin.

ITP Immune/idiopathic thrombocytopenia purpura

Epidemiology:

Etiology: provoked by **viral illness** in children.

Clinical Presentation: **isolated thrombocytopenia**

Diagnostic Mechanism: No diagnostic test

Diagnostic Results: diagnosis of exclusion.

Treatment: In adults, specific therapy if platelet < 20-30 OR bleeding.

First line = **corticosteroids**. **IVIg** if platelet < 10K OR bleeding.

Second line = **rituximab** to kill CD20+ cells. **Splenectomy**.